Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.

Shapiro, Geoffrey I

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Jan 2014 - 233-45 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

1557-3265

10.1158/1078-0432.CCR-13-1777 doi


Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--administration & dosage
Area Under Curve
Carcinoma, Non-Small-Cell Lung--drug therapy
Dose-Response Relationship, Drug
Female
Humans
Lung Neoplasms--drug therapy
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Staging
Phosphatidylinositol 3-Kinase--metabolism
Phosphoinositide-3 Kinase Inhibitors
Quinoxalines--administration & dosage
Signal Transduction
Skin Diseases--chemically induced
Sulfonamides--administration & dosage
Treatment Outcome